Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ADO-TRASTUZUMAB EMTANSINE: 8,699 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
8,699
Total FAERS Reports
1,199 (13.8%)
Deaths Reported
2,608
Hospitalizations
8,699
As Primary/Secondary Suspect
219
Life-Threatening
125
Disabilities
Prescription
Status

FDA Application: 125427 ·

First Report: 200411 · Latest Report: 20250919

What Are the Most Common ADO-TRASTUZUMAB EMTANSINE Side Effects?

#1 Most Reported
Nausea
780 reports (9.0%)
#2 Most Reported
Fatigue
774 reports (8.9%)
#3 Most Reported
Disease progression
750 reports (8.6%)

All ADO-TRASTUZUMAB EMTANSINE Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Nausea 780 9.0% 97 339
Fatigue 774 8.9% 81 285
Disease progression 750 8.6% 223 181
Diarrhoea 654 7.5% 113 396
Off label use 630 7.2% 165 251
Thrombocytopenia 519 6.0% 58 150
Death 509 5.9% 508 70
Neuropathy peripheral 506 5.8% 63 142
Headache 465 5.4% 44 224
Platelet count decreased 453 5.2% 48 168
Metastases to central nervous system 386 4.4% 45 84
Pyrexia 386 4.4% 72 215
Vomiting 380 4.4% 73 242
Drug ineffective 373 4.3% 46 58
Dyspnoea 346 4.0% 49 192
Pneumonia 341 3.9% 113 230
Epistaxis 327 3.8% 19 91
Pain 317 3.6% 35 140
Asthenia 313 3.6% 47 132
Weight decreased 309 3.6% 71 153

Who Reports ADO-TRASTUZUMAB EMTANSINE Side Effects? Age & Gender Data

Gender: 96.8% female, 3.2% male. Average age: 54.8 years. Most reports from: US. View detailed demographics →

Is ADO-TRASTUZUMAB EMTANSINE Getting Safer? Reports by Year

YearReportsDeathsHosp.
2004 1 0 0
2005 3 1 2
2007 3 0 0
2008 6 1 0
2009 23 1 3
2010 12 1 4
2011 13 1 7
2012 68 8 21
2013 179 27 76
2014 246 55 111
2015 426 85 233
2016 400 95 229
2017 368 60 196
2018 412 74 225
2019 448 68 214
2020 429 59 166
2021 449 51 188
2022 458 58 208
2023 358 50 150
2024 252 40 91
2025 72 10 26

View full timeline →

What Is ADO-TRASTUZUMAB EMTANSINE Used For?

IndicationReports
Breast cancer 2,342
Breast cancer metastatic 1,996
Her2 positive breast cancer 1,521
Product used for unknown indication 1,246
Her-2 positive breast cancer 868
Invasive ductal breast carcinoma 162
Invasive breast carcinoma 85
Neoplasm malignant 69
Breast cancer female 67
Breast cancer stage iv 46

ADO-TRASTUZUMAB EMTANSINE vs Alternatives: Which Is Safer?

ADO-TRASTUZUMAB EMTANSINE vs ADRIAMYCIN ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB-AVWA ADO-TRASTUZUMAB EMTANSINE vs ADVAIR ADO-TRASTUZUMAB EMTANSINE vs ADVAIR HFA ADO-TRASTUZUMAB EMTANSINE vs ADVIL ADO-TRASTUZUMAB EMTANSINE vs AFATINIB ADO-TRASTUZUMAB EMTANSINE vs AFINITOR ADO-TRASTUZUMAB EMTANSINE vs AFLIBERCEPT ADO-TRASTUZUMAB EMTANSINE vs AGALSIDASE ALFA

Official FDA Label for ADO-TRASTUZUMAB EMTANSINE

Official prescribing information from the FDA-approved drug label.